Factors and situations affecting the value of patient preference studies: semi-structured interviews in Europe and the US. by Whichello, C et al.
1 September 2019 | Volume 10 | Article 1009
ORIGINAL RESEARCH
doi: 10.3389/fphar.2019.01009
published: 18 September 2019
Frontiers in Pharmacology | www.frontiersin.org
Edited by: 
Tahir Mehmood Khan, 
University of Veterinary and 
Animal Sciences, 
Pakistan
Reviewed by: 
Florentina Ligia Furtunescu, 
Carol Davila University of 
Medicine and Pharmacy, 
Romania 
Robert L. Lins, 
Retired, Antwerp, Belgium
*Correspondence:
Chiara Whichello 
whichello@eshpm.eur.nl
†These authors share first authorship
‡These authors share last authorship
Specialty section: 
This article was submitted to 
Pharmaceutical Medicine 
and Outcomes Research, 
a section of the journal 
Frontiers in Pharmacology
Received: 14 May 2019
Accepted: 08 August 2019
Published: 18 September 2019
Citation: 
Whichello C, van Overbeeke E, 
Janssens R, Schölin Bywall K, 
Russo S, Veldwijk J, Cleemput I, 
Juhaeri J, Levitan B, Kübler J, 
Smith M, Hermann R, Englbrecht M, 
Hueber AJ, Comanescu A, 
Harding S, Simoens S, Huys I and 
de Bekker-Grob EW (2019) 
Factors and Situations Affecting 
the Value of Patient Preference 
Studies: Semi-Structured Interviews 
in Europe and the US. 
Front. Pharmacol. 10:1009. 
doi: 10.3389/fphar.2019.01009
Factors and Situations Affecting the 
Value of Patient Preference Studies: 
Semi-Structured Interviews in 
Europe and the US
Chiara Whichello 1*†, Eline van Overbeeke 2†, Rosanne Janssens 2, Karin Schölin Bywall 3, 
Selena Russo 4, Jorien Veldwijk 1, Irina Cleemput 5, Juhaeri Juhaeri 6, Bennett Levitan 7, 
Jürgen Kübler 8, Meredith Smith 9, Richard Hermann 10, Matthias Englbrecht 11,  
Axel J. Hueber 11, Alina Comanescu 12, Sarah Harding 13, Steven Simoens 2,  
Isabelle Huys 2‡ and Esther W. de Bekker-Grob 1‡
1 Erasmus School of Health Policy & Management and Erasmus Choice Modelling Centre, Erasmus University, Rotterdam, 
Netherlands, 2 Department of Pharmaceutical and Pharmacological Sciences, University of Leuven, Leuven, Belgium,  
3 Center for Research Ethics & Bioethics, Uppsala University, Uppsala, Sweden, 4 Applied Research Division for Cognitive 
and Psychological Science, IEO European Institute of Oncology IRCCS, Milan, Italy, 5 Belgian Health Care Knowledge 
Centre, Brussels, Belgium, 6 Sanofi, Bridgewater, NJ, United States, 7 Global R&D Epidemiology, Janssen Research & 
Development, Titusville, United States, 8 Quantitative Scientific Consulting, Marburg, Germany, 9 Global Patient Safety and 
Labeling, Amgen Inc., Thousand Oaks, CA, United States, 10 Astra Zeneca, Gaithersburg, MD, United States, 11 Department 
of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) and 
Universitätsklinikum Erlangen, Erlangen, Germany, 12 Community Health Association, Bucharest, Romania, 13 Global Patient 
Safety, Takeda, London, United Kingdom
Objectives: Patient preference information (PPI) is gaining recognition among the 
pharmaceutical industry, regulatory authorities, and health technology assessment (HTA) 
bodies/payers for use in assessments and decision-making along the medical product 
lifecycle (MPLC). This study aimed to identify factors and situations that influence the 
value of patient preference studies (PPS) in decision-making along the MPLC according 
to different stakeholders.
Methods: Semi-structured interviews (n = 143) were conducted with six different 
stakeholder groups (physicians, academics, industry representatives, regulators, HTA/
payer representatives, and a combined group of patients, caregivers, and patient 
representatives) from seven European countries (the United Kingdom, Sweden, Italy, 
Romania, Germany, France, and the Netherlands) and the United States. Framework 
analysis was performed using NVivo 11 software.
Results: Fifteen factors affecting the value of PPS in the MPLC were identified. These 
are related to: study organization (expertise, financial resources, study duration, ethics 
and good practices, patient centeredness), study design (examining patient and/or 
other preferences, ensuring representativeness, matching method to research question, 
matching method to MPLC stage, validity and reliability, cognitive burden, patient 
education, attribute development), and study conduct (patients’ ability/willingness 
to participate and preference heterogeneity). Three types of situations affecting the 
use of PPS results were identified (stakeholder acceptance, market situations, and 
clinical situations).
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INTRODUCTION
Recently, the use of patient preference information (PPI) in drug 
development and assessments has gained attention (Meredith 
et al., 2016). PPI is defined by the United States (US) Food and Drug 
Administration (FDA) as: “qualitative or quantitative assessments 
of the relative desirability or acceptability to patients of specified 
alternatives or choices among outcomes or other attributes that 
differ among alternative health interventions” (FDA, 2016). Key 
stakeholders, including the pharmaceutical and medical device 
industry, regulatory authorities, health technology assessment 
(HTA)/payers, reimbursement agencies, academia, healthcare 
professionals, and patient representatives, are recognizing the 
value of PPI in assessments and decision-making along the 
medical product lifecycle (MPLC) (Medical Device Innovation 
Consortium (MDIC), 2015; Abelson et al., 2016).
PPI can be used in every phase of the MPLC (Medical Device 
Innovation Consortium (MDIC), 2015; Marsh, 2016). Some 
examples of applications include: identifying unmet medical 
needs (Medical Device Innovation Consortium (MDIC), 2015; 
FDA, 2016; Selig, 2016), informing the selection of endpoints, and 
informing benefit-risk assessments (Medical Device Innovation 
Consortium (MDIC), 2015; FDA, 2016; Stamuli et al., 2017; 
Bloom et al., 2018) and in HTA (Kievit et al., 2017; Muhlbacher 
and Sadler, 2017; Marsh et al., 2018). PPI can give insights into 
the trade-offs that patients make between benefits and risks and 
show the relative importance of outcomes for patients (Puhan 
et al., 2015; Minion et al., 2016; Marsh et al., 2017).
PPI can be obtained through many different preference 
exploration (qualitative) or elicitation (quantitative) methods 
(Hockley et al., 2014; Medical Device Innovation Consortium 
(MDIC), 2015; FDA, 2016; Gutknecht et al., 2016). Exploration 
methods are recommended for concept exploration and gaining 
in-depth knowledge on the value of medical products (Facey 
et al., 2010; Egbrink and IJzerman, 2014; Medical Device 
Innovation Consortium (MDIC), 2015). Elicitation methods 
can quantify personal preferences and can allow for statistical 
analysis and possibly the detection of preference heterogeneity 
among patients (Puhan MA, 2012; Medical Device Innovation 
Consortium (MDIC), 2015; FDA, 2016).
Despite prior guidance on the review and research practices 
of patient preference studies (PPS) (FDA, 2016; Medical Device 
Innovation Consortium (MDIC), 2015; Bridges et  al., 2011), 
systematic integration and acceptance of PPI into decision-
making are still pending. Most industry, HTA/payers and 
regulators “have key uncertainties regarding the validity, 
representativeness, and robustness of preference studies to inform 
deliberative decision-making” (de Bekker-Grob et al., 2017). 
Therefore, structured insights from all relevant stakeholders on 
the design and conduct of PPS are currently needed. This study 
aimed to gather stakeholders’ views on important factors and 
situations that influence the value and role of PPS in assessments 
and decision-making. By addressing these factors and situations, 
decision-makers can be advised on how to conduct and integrate 
more robust PPS, increasing the potential for their integration 
along the MPLC.
METHODS
Design
Interviews were conducted with six stakeholder groups: industry, 
HTA/payers, regulators, academia, physicians, and a combined 
group of patients, patient representatives, or patients’ caregivers. 
Interviews were conducted in eight countries with heterogeneous 
healthcare systems. Interviews with patients, patient representatives, 
caregivers, and physicians were conducted in different disease 
contexts (Table 1). Higher interview quota (n  = 24) were set 
for “primary” countries than represented four different regions 
of Europe. A smaller quota (n = 12) were set for “auxiliary” 
countries, which served to confirm observations from the 
primary countries (Table 1).
Participant Recruitment
Participants were selected based on predefined inclusion criteria 
(Supplemental Material: Appendices I-II) to enable selection 
of interviewees with the necessary experience or expertise to 
answer our research questions and promoting heterogeneity 
across the sample. Our interviewees were recruited through 
purposive sampling and snowballing recruitment techniques 
(Morgan, 2008).
Conduct
Two interview guides (Supplemental Material: Appendices 
IV-V) were developed based on the research questions and 
a literature review (van  Overbeeke et al., 2019). One guide 
using technical language was written for industry, regulators, 
HTA/payer representatives, and academics, and one using 
plain language for patients, caregivers, physicians, and 
patient representatives. The interview guides were translated 
from English into six other languages. Interviews with 
patient representatives, patients, caregivers, and physicians 
were conducted in their native language. These guides were 
translated back to English for a consistency check. Interviews 
with others were conducted in English, unless they only 
felt comfortable speaking their native language. To ensure 
comprehension of the guides, five reviews of the guide and 
Conclusion: The factors and situation types affecting the value of PPS, as identified 
in this study, need to be considered when designing and conducting PPS in order to 
promote the integration of PPI into decision-making along the MPLC.
Keywords: patient preferences, drug life cycle, decision-making, health technology assessment, benefit risk 
assessment, market authorization 
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pilot interviews were conducted by targeted stakeholder 
members. Written informed consent was obtained from all 
participants before the start of the interviews. The interviews 
were conducted via telephone, teleconference, or face-to-face. 
Interviews were audio-recorded, transcribed verbatim, and 
pseudonymized. Non-English transcripts were translated to 
English.
Analysis
Transcripts were analyzed through framework analysis (Ritchie and 
Spencer, 2002; Gale et al., 2013) using NVivo (QSR International 
Pty Ltd., 2012). The data were interpreted for patterns, consensuses, 
and critical observations across the stakeholder groups, which 
created thematic “codes.” First, 2 researchers (CW; EvO) examined 
54 transcripts during a “familiarization process” (Ritchie and 
Spencer, 2002) through which an overview of the collected data was 
established, and the researchers became aware of key themes and 
concepts which are made into thematic “codes.” Due to the volume 
of data, it is common for researchers conducting framework 
analysis to only familiarize themselves with a section of data 
(Wolka et al., 2017); in this case, roughly one third of the transcripts 
(n = 54) was used for familiarization. Next, a thematic framework 
was identified. Coding was applied to six transcripts (one from 
each stakeholder group) by two researchers (CW; EvO), in order 
to confirm the codes identified from the familiarization process, 
and also to confirm deductive codes formed from a previous 
systematic review regarding factors and situations influencing 
the value of PPS (van Overbeeke et al., 2019). Additional open-
coding originating from these 6 transcripts were combined with 
the familiarization process codes and the literature codes to create 
a final coding list (Supplemental Material: Appendix VI), which 
was then applied to all 143 transcripts by 5 researchers (CW, EvO; 
KB; RH; MS). Portions or sections of text that corresponded to a 
theme were indexed and placed in charts with headings reflecting 
TABLE 1 | Planned design of the interviews.
Country classes Country Interview quota Interview quota per stakeholder 
group*
Disease context**
Primary countries
(with a 24 interviewee quota)
Italy 24 4 Lung cancer
Romania 24 4 Cardiovascular disease
Sweden 24 4 Rheumatoid arthritis
United Kingdom 24 4 Muscular dystrophy
Auxiliary countries
(with a 12 interviewee quota)
France 12 2 Lung cancer
Germany 12 2 Rheumatoid arthritis
Netherlands 12 2 Muscular dystrophy
United States 12 2 Cardiovascular disease
*Six stakeholder groups were interviewed in every country. These stakeholder groups included the pharmaceutical and medical device industry, HTA/payers, regulators, academia, 
physicians, and the combined group of patient representatives, patients, and patients’ caregivers.
**Only for interviews with patients, patient representatives, caregivers, and physicians.
TABLE 2 | Characteristics of interviewees.
Interviewees (n = 143) Patients, patient repr. 
and caregivers (n = 24)
Industry repr. 
(n = 24)
Regulators 
(n = 23)
HTA/payer repr. 
(n = 24)
Physicians 
(n = 24)
Academics 
(n = 24)
n % n % n % n % n % n %
Country                        
 Italy (n = 24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17%
 Romania (n = 23) 4 17% 4 17% 3 13% 4 17% 4 17% 4 17%
 Sweden (n = 24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17%
 UK (n = 24) 4 17% 4 17% 4 17% 4 17% 4 17% 4 17%
 France (n = 12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8%
 Germany (n = 12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8%
 Netherlands (n = 12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8%
 US (n = 12) 2 8% 2 8% 2 9% 2 8% 2 8% 2 8%
Disease area*                        
 Lung cancer 6 25% NA NA NA 6 25% NA
 Rheumatoid arthritis 6 25% NA NA NA 6 25% NA
 Muscular dystrophy 6 25% NA NA NA 6 25% NA
 Cardiovasc. disease 6 25% NA NA NA 6 25% NA
Self-reported familiarity 
with PP
                       
 Very familiar/Expert 1  4% 4 17% 3 13% 2  8% 0  0% 12 50%
 Moderately familiar 7 29% 11 46% 13 57% 16 67% 6 25% 7 29%
 Not familiar 16 67% 9 38% 7 30% 6 24% 18 75% 5 21%
Cardiovasc., cardiovascular; NA, not applicable; PP, patient preferences; Reg., regulators; repr., representatives; HTA, Health Technology Assessment; UK, United Kingdom; US, 
United States; *specific disease areas w here only applicable to patients, patient representatives, caregivers, and physicians.
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these themes. These charts were then analyzed and interpreted 
for common attitudes and opinions of the respondents, with 
comparisons being made inside stakeholder groups and countries. 
RESULTS
In total, 143 interviews were conducted, and interview quota 
was reached for all stakeholder groups and countries except 
for Romanian regulators (Table 2). Factors were identified 
along three stages of PPS: organization, design, and conduct 
(Figure  1). In addition, challenges and solutions relating to 
these factors were identified (Table 3). Situations were identified 
during the last stage: communication and use of results. These 
stages were identified through literature (van Overbeeke et al., 
2019) and confirmed through interview responses.
Factors Relating to Study Organization
Five factors relating to the organization of PPS were identified, 
namely: (1) expertise of staff, (2) financial resources, (3) 
study duration, (4) ethics and good practices, and (5) patient 
centeredness (Figure 1, Table 3). The first four factors were 
anticipated and will not be exhaustively detailed in the results, 
because they are factors that influence the value of any scientific 
study. Although they are important factors, they are not unique 
to PPS. Further information about these factors’ current 
implementation in PPS is summarized in the systematic review 
by van Overbeeke et  al. (van Overbeeke et al., 2019). The fifth 
factor, patient centeredness, was more specific to PPS. Patient 
centeredness in study organization is key to a successful PPS, 
since this should be the focus of the study. Patients are invaluable 
to informing the research questions, improving recruitment, and 
ensuring the comprehensibility of information and questions 
given to patients (van Overbeeke et al., 2019). Interviewees 
across all stakeholder groups and countries, except for Romania, 
expressed the importance of having patients and/or patient 
representatives involved in the design and conduct, because they 
have the most real-life experience with their own condition.
Factors Relating to Study Design
Eight factors relating to the design of PPS were identified 
(Figure 1). All stakeholder groups across all countries felt that 
study design is a crucial phase of PPS.
1. Examining patient and/or other preferences
  All interviewees were asked whose preferences should be measured, 
and their answers included patients, patient organizations, the 
public, caregivers, physicians, and combinations of these categories. 
Four interviewees discussed how the population must satisfy the 
research question. The preferences of family caregivers could 
be important in instances when caregivers make most of the 
medical decisions because patients cannot express themselves 
or their preferences may not be reliable (e.g., children or 
impaired cognitive abilities). Although caregiver preferences 
can sometimes reflect patient preferences, they also have their 
own preferences which could be different from the patient’s 
preferences. HTA/payer representatives, patients, industry 
representatives, and academics discussed preferring general 
public preferences instead of PPI, or a combination thereof, 
in the context of healthcare expenditure, budget allocation, 
and reimbursement. A UK HTA/payer representative stated 
they must consider “all of the uses of the NHS [National Health 
Service] rather than just the particular patient group who is in 
front of them.” Five HTA/payer representatives assumed that 
patient preferences are incorporated satisfactorily and “built 
in” (UK) through QALYs or EQ5D measures, despite their 
calculation frequently incorporating public utility values for 
quality of life attributes as opposed to patient utilities for 
FIGURE 1 | Factors and situations influencing the value and role of patient preference studies (PPS) along the medical product lifecycle (MPLC).
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TABLE 3 | Challenges and solutions identified in the factors affecting the value of patient preference studies (PPS).
  Factors Challenge Solution
O
rg
an
iz
at
io
n 
fa
ct
o
rs
Expertise PP studies are complex and need to have correct analysis 
and interpretation.
Have a multidisciplinary team that has experience with 
the disease in question and patient preference study 
conduct and/or methodologies.
Financial resources PP studies are costly, and funding is difficult to obtain. Ensure enough budget to not compromise recruitment 
and sample size.
Study duration Patient recruitment is time consuming, particularly with rare 
diseases.
Consider recruiting through many multiple channels 
(healthcare professionals, internet calls, patient 
organizations, national registries, and clinical trials). It 
is possible to conduct a complete patient preference 
study between 6 and 12 months. 
Patient centeredness Patient centeredness needs to be integrated into study 
design.
Allow patients and/or patient representatives to be 
involved in the design of PP studies.
Ethics and good practices Obtaining ethical approval is often a barrier for researchers. 
Privacy concerns might make patients hesitant to 
participate. Stakeholders are concerned about industry bias.
Ensure ethical approval is always obtained. Ensure 
anonymous, confidential data collection and be 
transparent about how patient data is handled. Involve a 
neutral party to balance potential biases.
D
es
ig
n 
fa
ct
o
rs
Examining patient and/or other 
preferences
It is not always known whose preferences need to be 
studied.
This largely depends on the research question; if patient 
preferences need to be known, then the sample should 
consist out of patients. In some cases, however, PP can 
be supplemented with caregiver/public preferences
Ensuring representativeness Ensuring representativeness and generalizability is difficult 
when preferences are largely subjective.
Where possible, examine a large sample size and 
include patients that have experience with or sufficient 
knowledge about the disease and are informed about 
treatments and/or drug development.
Matching method to research 
question 
Selecting a method appropriate for a research question There is no “gold standard” method, and matching a 
method to the research question depends on what is 
attempting to be measured, and what form the results 
need to be. Some favor methods that can handle 
hypothetical scenarios, can quantify trade-offs, or 
include monetary valuations.
Matching method to MPLC 
stage 
Selecting a method appropriate for an MPLC stage Qualitative methods are thought to be more appropriate 
for earlier stages, to identify attributes, and then 
followed up with quantitative methods to quantify these 
attributes at later stages.
Validity and reliability Validity is important and needs to be maintained. Scientific consensus on an international level needs to 
standardize validity, including method, criteria, internal, 
and external validity. Despite there being no “gold 
standard” method, there still needs to be a standardized 
way to evaluate all methods. 
Cognitive burden Cognitive burden needs to be taken into consideration to 
involve patients with all ranges of abilities.
Try to limit the use of elements that add greater 
cognitive burden: hypothetical scenarios, complex 
probabilities, or percentages, describing complex 
stages of the MPLC, repeating the same type of 
question many times, long surveys/interviews with no 
breaks, abstract ideas without concrete examples, and 
surveys that cannot be completed at home.
Patient education Patients’ knowledge is often not sufficient to contribute 
meaningful answers.
Utilize educational tools, perhaps in video or other 
format, to instruct patient preference exercises.
Attribute development Attributes need to contain important information for 
decision-makers, but also be comprehensible to patients.
Too many attributes in one choice task in some 
elicitation methods, such as a DCE, can become 
burdensome to patients. Ensure easily interpretable 
attributes by involving patients and/or representatives in 
their construction.
C
o
nd
uc
t 
fa
ct
o
rs
Patient ability and willingness to 
participate
Participant recruitment is difficult if patients are unable or 
unwilling to participate.
Recruit patients through multiple channels (healthcare 
professionals, internet calls, patient organizations, 
national registries, and clinical trials) and offer studies 
that patients can complete at home, or offer travel 
reimbursement schemes.
Preference heterogeneity Heterogeneity in PP studies is difficult to address in 
decision-making.
Heterogeneity is inherent and must be sufficiently 
captured or quantified through PP exploration or 
elicitation or methods.
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treatment outcomes. An EU industry representative stated 
that when it is the objective to elicit patient preferences, the 
general public should not be included.
2. Ensuring representativeness
  Representatives from industry, HTA/payers, regulatory, 
academia, patients, and patient organizations across all 
countries expressed that it is crucial to have a patient sample 
representative of the actual patient population targeted with 
the treatment. All stakeholder groups across all countries 
had opinions about what constitutes as ideal characteristics 
of the patient sample, although this depends largely on 
the research question. Almost all participants agreed that 
patients should have experience with the disease, although 
this is not as important in contexts like disease prevention. 
Eighteen participants believed participants should have 
experience with treatment, stating that this results in more 
“reliable” (UK, regulator) preferences. Fourteen participants 
stated experience with treatment was less important. 
Other characteristics of an ideal sample included covering 
multiple countries of residence, if generalizability across 
countries is desired. Six interviewees (industry, regulatory, 
academia, and HTA/payer) expressed concern that the 
subjective nature of PPI generates a lower generalizability. 
US and EU academics, an EU HTA/payer representative, 
and an EU regulator explained how recruitment through 
patient organizations can lead to samples of highly 
motivated patients, and recruitment through clinical trials 
can give samples restricted by predetermined inclusion 
or exclusion criteria, both of which are not representative 
of the patient population. A solution, according to the 
regulator, might be to recruit 50% patient organizations 
and 50% “everyday” patients.
3. Matching the method to the research question
  The majority of industry, HTA/payer, regulators, and 
academic representatives mentioned that there is no 
single “gold standard” preference exploration (qualitative) 
or elicitation (quantitative) method. According to 
one academic, selecting a method is in itself “a trade-
off” because “none of them are perfect … [or] offer you a 
guarantee of being better over any other one” (UK). The 
ability to quantify trade-offs was thought to be paramount 
in elicitation methods by many stakeholder groups, 
particularly academics. An EU physician was adamant 
that an elicitation method needs to be equipped to handle 
hypothetical scenarios, including drugs that are not yet 
available, and must include the option to not receive any 
treatment. This physician felt this was extremely applicable 
to conditions that have limited treatment options. One EU 
academic required elicitation methods to assess marginal 
rate of substitution to determine maximum acceptable risk. 
Five academics and one HTA/payer representative from 
Sweden and Germany advocated for elicitation methods 
that incorporate a monetary valuation, such as willingness-
to-pay. EU academic and industry representatives indicated 
that elicitation methods are seen as more “robust” (US, 
industry), “objective” (Germany, industry), and “acceptable 
by [sic] the medical … community” (Netherlands, academic) 
and more likely to “convince a payer” (France, academic).
4. Matching the method to the MPLC stage
  Exploration methods were thought better suited for early 
MPLC phases for exploring heterogeneous data, defining 
value frameworks, or identifying endpoints or attributes, 
examining cultural heterogeneity and subjective experiences. 
Most interviewees from academia and industry argued that a 
mixed-method approach is necessary, discovering attributes 
and levels early in the MPLC through exploration methods 
to “inform” (US, academia) elicitation studies during phase 
III or IV. Elicitation methods were thought to “refine quality [ 
… ] with numbers” (Italy, regulator) by quantifying trade-offs, 
obtaining the strength of a preference, ranking or weighing 
an endpoint, and/or comparing decision pathways. Two UK 
HTA/payer representatives mentioned that they are most 
familiar with elicitation methods during appraisals.
5. Validity and reliability
  Most interviewees from all countries, especially HTA/
payer representatives and academics, felt validity was 
extremely important, including method validity, criteria 
validity, internal validity, and external validity. EU HTA/
payer representatives, a regulator, and two industry 
representatives expressed a need for international scientific 
consensus regarding evaluating rigor of methodologies in 
a “standardized, validated way—accepted by everybody, all 
stakeholders” (France). One academic assured that studies 
published in articles undergo quality checklists for validity 
but also suggested that piloting should be conducted within 
studies for quality and validity checks. A US regulator 
pointed out that some methods have higher validity than 
others and suggested that the degree of rigor should be “fit for 
purpose,” meaning the level of validity should be proportional 
to the risk or invasiveness of the medical product. A US 
industry member explained how external validity is often 
not necessary for internal decision-making. An EU academic 
is worried that use of hypothetical situations leads to low 
external validity.
6. Cognitive burden
  All stakeholder groups emphasized that cognitive abilities 
of patients must be considered when designing preference 
studies, particularly for diseases associated with cognitive 
impairment or neuromuscular fatigue. This assures validity 
of the data but also places value in the preferences of all 
patients, regardless of cognitive ability. Many interviewees 
insisted that patients with cognitive issues should not be 
excluded, with an EU physician stating that stakeholders 
“have to get [sic] extra input to try and find out exactly what 
their views are” (UK). A physician, regulatory, and HTA/
payer representative mentioned that survey fatigue should be 
avoided. Two patients said that patients often have different 
preferences depending on how they are feeling that particular 
day (UK patient and UK caregiver). Several cognitively 
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burdensome situations were highlighted by academics, 
regulators, industry, and HTA representatives, including 
(1) hypothetical scenarios, (2) complex probabilities or 
percentages, (3) complex stages of the drug life cycle, (4) 
many repetitions of similar questions with different phrasing, 
(5) long surveys with no breaks, (6) absence of concrete 
examples, and (7) surveys that cannot be completed at home. 
A US academic expressed, “a poorly designed study that was 
poorly understood by the users could result in a worse decision 
than if there had been no study what-so-ever.”
7. Patient education
  Four EU and US industry members commented that patients’ 
knowledge is often not sufficient to contribute meaningful 
answers. However, other stakeholders, including patients 
themselves, recognized that the responsibility of patient 
education does not lie with the patients, but with the 
study designers, who should ensure comprehensibility. An 
EU industry member advised utilizing educational tools, 
in video or other format, to instruct patient preference 
exercises. A US academic stated “we need to figure out 
how to make the instrument as comprehensible as possible 
to respondents who may have a very low educational 
attainment but still be accurate enough that we can map 
the attributes and levels to clinical outcomes,” expressing 
the need to strike a right balance. Two EU stakeholders 
recognized that informing patients without contributing 
bias or “influenc[ing]” the patient (Germany, physician) is 
“a challenge” (Sweden, regulator).
8. Attribute development
  All stakeholders who expressed an ideal number of 
attributes for PPI elicitation studies thought that it should 
be between three and six attributes. Any more than seven, 
and the cognitive burden can become unmanageable, or the 
patients “[simplify] characteristics” (US, industry), affecting 
validity. Both EU and US interviewees mentioned standard 
attributes to incorporate like quality of life, overall survival 
rates, progression-free survival rates, or other symptomatic 
evaluations. An EU academic also advocated for the 
inclusion of “willingness-to-pay” (WTP) features, as well 
as the level of convenience of managing conditions. An EU 
physician suggested to include the products’ administration 
frequency. Most representatives from different stakeholder 
groups emphasized the importance of constructing “easily 
interpretable” (Netherlands, regulator) and “patient-user 
friendly” (UK, regulator) questions, thereby measuring their 
preferences accurately. Two EU representatives spoke about 
making sure not to “steer certain answers” (UK, industry) and 
recognized that patients can be susceptible to the particular 
question ordering. A US academic strongly warned against 
using ambiguous attribute levels such as “mild, moderate, 
and severe.” A US regulator explained “Patients who had 
experience of the disease should be essential in determining the 
type of questions, and for example, attributes [ … ] also, the 
wordings and the communication part”.
Factors Relating to Study Conduct
Two factors relating to the conduct of PPS will be examined 
(Figure 1), namely: (1) patients’ ability and willingness to 
participate and (2) preference heterogeneity.
1. Patients’ ability and willingness to participate
  Interviewees identified different hurdles to patient recruitment 
including lack of resources, the possibility of people dropping 
out (or passing away) during the course of recruitment, 
fraudulent participants, and a hesitation of patients to discuss 
traumatic elements of their disease or condition. EU patients, a 
caregiver, and an industry representative said newly diagnosed 
patients or patients in severe, late stages of illness might not 
want to participate. In the context of myotonic dystrophy, an 
EU caregiver explained “It can take a long time for them to 
accept [the diagnosis] and to understand it” (UK). A US HTA/
payer representative stated “One of the biggest issues is finding 
the patient” and explained that, normally, 1 month is given for 
recruitment, although two EU academics and two EU physicians 
stated that it can take years for rare diseases. Multiple channels 
for recruitment were proposed by interviewees including 
healthcare professionals, internet calls, patient organizations, 
national registries, and clinical trials. To facilitate recruitment, 
two EU patients have suggested to conduct studies from home 
or reimburse travel and hotel costs.
2. Preference heterogeneity
  Almost all interviewees argued that preference heterogeneity, or 
the extend that preferences vary across individuals, is inevitable 
and “inherent” (UK, industry) due to differences in treatment 
experience, disease experience, cultures and countries, 
education, socio-economic status, family and support systems, 
and beliefs and religions. Two regulators (EU), two academics 
(EU and US), and three industry representatives (EU) stated 
that capturing heterogeneity is complex and is often difficult to 
integrate into decision-making. Four industry representatives 
(EU and US), three regulators (EU), and three HTA/payers 
(EU) argued that heterogeneity is actually desirable and is “a 
gift” (HTA/payer, Germany). It enables subgroup identification 
and exploration of opinions. An EU regulator stated that 
heterogeneity is only a problem if not taken into account. 
Three EU regulators and a US industry representative stated 
that heterogeneity investigation requires larger sample sizes. 
A patient, academic, and a regulator (EU and US) argued that 
PPI should be measured at multiple points in time to examine 
preference variation. An EU academic stated that preference 
studies should always conduct a latent class or other model 
of standard deviation to explore preference heterogeneity and 
allow for subgroup analysis.
Situations Relating to Communication  
and Use of PPS Results
Three types of situations were identified that may have an 
influence on the use of PPS results in decision-making along 
the MPLC (Figure 1), including (1) stakeholder acceptance, 
(2) clinical situations, and (3) market situations. Participants 
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were asked directly whether there are any situations where the 
use of patient preferences could be more useful or less useful, 
and the following situations were discussed.
1. Stakeholder acceptance
  Stakeholder acceptance, or the lack thereof, is a significant 
situation that can affect the use of PPS results along the 
MPLC. A patient representative, HTA/payer representative, 
and academics (EU, US) expressed that a “cultural change” 
(UK, HTA/payer) is needed to have assessors look at these 
data, because they are often “narrow-minded” (US, academia) 
about considering PPI. A patient and two regulators expressed 
the need for training assessors on the topic of PPI. Several 
interviewees, particularly HTA/payers and regulators, were 
reluctant towards PPI and gave more importance to other 
criteria, such as cost-effectiveness and clinical outcomes. 
Three interviewees questioned the ability of patients to provide 
valuable input since they are “not rational,” “too emotional,” 
(Romania, academic) and “not able to make the best decisions 
for themselves” (US, HTA/payer). Almost half of Romanian 
interviewees mentioned that PPI do not have a place in the 
MPLC and was “never [ … ] important in Romania” (industry).
2. Clinical situations
  PPI was perceived to be particularly useful in the context 
of chronic diseases, rare diseases, remission disorders, high 
unmet medical needs, unclear benefit-risk balance (both in 
terms of moderate benefits/high risks or heterogeneous drug 
profiles), limited availability of clinical (or other) information, 
end-of-life treatments, invasive treatments, and treatments 
with subjective endpoints. Two EU regulators believed that 
PPI is less important in the case of medical devices, especially 
the less invasive they are. An EU patient stated the opposite, 
explaining that patients have to use these devices every day. 
Two EU regulators and an EU academic believed that new or 
innovative products would benefit from PPI, although two 
other EU regulators disagreed, stating that patients would 
not be familiar enough with these products. Other contexts 
where PPI was perceived to be less useful include biological 
fluids, diagnostics, non-invasive treatments and medical 
devices, prevention medicine, surgical interventions, 
therapies with no clinical evidence (such as homeopathy), 
clear differences between new product and reference, new 
drugs with no added value compared to those on the market, 
acute disorders (excluding cancer), or situations with a clear 
benefit-risk balance.
3. Market situations
  Two EU industry representatives and one US HTA/payer 
representative stated that PPI would be especially important 
in crowded therapeutic markets where trade-offs will be made 
between products, although one EU HTA/payer representative 
believed PPI would not add significant value in this situation. 
An EU industry representative stated that PPI would be 
less useful during significant changes in the therapeutic 
market. An EU regulator stated that they would also not be 
as important when no medical alternatives are available, like 
for with orphan drugs, although patient acceptance to the 
treatment can still be measured. Another EU regulator stated 
that it might not be useful to examine PPI on sensitive topics 
with public controversy.
DISCUSSION
Through 143 semi-structured interviews with 6 stakeholder 
groups in 8 countries, we identified 15 factors and 3 types 
of situations that can influence the value and role of patient 
preferences in assessments and decision-making along the 
MPLC. Our results offer key insights into the barriers hindering 
the integration of patient preferences throughout assessments 
and decision-making in the MPLC, and our interviewees also 
expressed solutions as to how these challenges can be overcome 
(Table 3). Frequently cited factors included matching method to 
research question and MPLC stage, validity, cognitive burden, 
and preference heterogeneity.
Our results confirm the statements of the FDA guidance 
on PPI (FDA, 2016) and other studies (Postmus et al., 2016; 
Wolka et al., 2017) regarding the involvement of patients and 
patient representatives in the design and conduct of preference 
studies. This leads to a better comprehensibility of the questions 
given to patients, improves recruitment, and ensures correct 
interpretation and communication of results. The FDA guidance 
on PPI (FDA,  2016) also indicates that exploration methods 
would be most useful during discovery, which is confirmed 
by our results. Our interviewees believed elicitation methods 
were suited for later phases in the MPLC although some argued 
that mixed-method studies would be beneficial. The use of 
elicitation methods is well documented in regulatory benefit-
risk assessments (van Til and Ijzerman, 2014) and HTAs 
(Weernink et al., 2014). However, HTA/payers also often utilize 
qualitative PPI or patient involvement (Mott, 2018), which was 
also supported by our results.
Interviewees provided insightful guidance into the various 
elements of a patient preference study (PPS) that could 
increase cognitive burden, such as hypothetical scenarios and 
complex probabilities or percentages, which the FDA guidance 
on PPI also includes (FDA, 2016). Some interviewees preferred 
at-home surveys, although several authors (Tervonen et al., 
2017; Postmus et al., 2018) argue that survey administration 
via interviews or workshops can provide beneficial in-person 
support to patients. Some interviewees highlighted the 
importance of always using patient preferences instead of 
public utilities, except in situations where proxies to patients 
may be required. Others emphasized using public utilities 
in economic evaluations to ensure the applicability to more 
general allocation decisions. The issue of public versus patient 
preferences in health economic evaluations remains a pressing 
issue of debate (Faggioli et al., 2011; FDA, 2016).
Interviewees indicated that there is a lack of guidance on 
the validity assessment of preference methods, confirming 
similar findings in the MDIC PCBR report (Medical Device 
Innovation Consortium (MDIC), 2015). Conceptual models 
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created for validity assessments of some methods are currently 
being developed (Janssen et al., 2017). Capturing preference 
heterogeneity and allowing for the identification for subpopulations 
will increase the value of PPS for benefit-risk assessments and 
HTA (Medical Device Innovation Consortium (MDIC), 2015; 
FDA, 2016; Postmus et al., 2016; Kievit et  al., 2017). Interviewees 
suggested that capturing preference heterogeneity requires 
larger sample sizes and the use of latent class or other models 
of standard deviation. Janssen et al. (2017) also concluded that 
advanced statistical methods might improve the understanding of 
preference heterogeneity in benefit-risk assessments, although the 
number of subpopulations that can be evaluated is limited.
The identified market situations influencing the value of PPI 
support the concept of preference sensitive decisions, described 
by the MDIC PCBR report as “[decisions] … in which there are 
multiple diagnostic or treatment options, and the decision which 
option to pursue depends upon the particular preferences of the 
decision maker” (Medical Device Innovation Consortium (MDIC), 
2015). They encompass situations when no option is clearly superior 
over a plausible range of preferences and/or the evidence supporting 
one option over others is considerably uncertain. In addition, our 
findings confirm the statements of Hollin et al. (Hollin et al., 2017), 
the FDA guidance on PPI (FDA, 2016), and the MDIC PCBR 
report (Medical Device Innovation Consortium (MDIC), 2015) that 
populations with unmet medical needs and rare diseases are specific 
situations where PPI is very valuable.
Strengths and Limitations
This study’s fundamental strength originates from interviewing 
international experts in a variety of fields relating to every stage of 
the MPLC. Additionally, we interviewed patients, caregivers, and 
patient representatives, representing potential participants in PPS.
Recruitment of interviewees was mostly done through the 
PREFER consortium and snowballing. Participants might have 
had an upfront interest PPI, creating a non-random sampling 
bias. A limited sample of each stakeholder group per country was 
interviewed, thus is not representative of the whole stakeholder 
population. The self-reported familiarity with the topic of PPI 
differed among stakeholder groups and countries (Table 2). 
Participants with low self-reported familiarity may have provided 
less informative insights. In Romania, 74% of interviewees stated 
they were “not familiar” with PPI. However, all participants were 
recruited based on their significant experience as members of key 
stakeholder groups in the MPLC. Even if a participant had limited, 
direct experience with PPS, their experience with different stages of 
the MPLC, the incorporation of evidential data at these stages, or 
their interaction with patients, is highly relevant when considering 
the potential for PPI integration, and the factors that might be 
supporting or hindering this integration.
The semi-structured nature of the interviews created a flexible 
rapport between interviewer and interviewee, allowing follow-up 
questions to be asked. However, not all factors and situations were 
discussed with every interviewee since some opted not to answer 
questions. For example, due to time constraints, participants 
were unable to elaborate on the reasons why PPI is useful in some 
clinical and market situations, and instead listed them.
There was variation between interviews since eight interviewers 
conducted the interviews in seven different languages. Qualitative 
methodologies rely on subjective experiences and perspectives 
of participants in order to observe phenomena with context and 
detail. Therefore, the results of these interviews represent the 
thoughts and opinions of the interviewees and may not always 
be objective or generalizable to every organization or country. 
However, the large number of 143 interviews contributed to 
triangulating the data and examining an accurate account of 
the current status of PPI in the MPLC. Further research is 
recommended to contextualize these stakeholder comments with 
each country’s unique healthcare system and identify when PPI 
can be best integrated into the MPLC.
CONCLUSIONS
Many situations and factors need to be taken into account when 
designing and conducting PPS in order to obtain valuable results 
that can be used in decision-making. By examining the guidance 
given by 143 stakeholders with unique expertise, more robust 
PPS can be performed in order to incorporate PPI successfully 
into the MPLC. Moreover, these results can help medical product 
developers to decide, whether or not and how to include PPS 
in their development plan, avoiding waste of resources and the 
unnecessary exhaustion of patient populations.
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